Lenacapavir
- Generic Name
- Lenacapavir
- Brand Names
- Sunlenca
- Drug Type
- Small Molecule
- Chemical Formula
- C39H32ClF10N7O5S2
- CAS Number
- 2189684-44-2
- Unique Ingredient Identifier
- A9A0O6FB4H
- Background
HIV/AIDS remains an area of concern despite the introduction of numerous successful therapies, mainly due to the emergence of multidrug resistance and patient difficulty in adhering to treatment regimens. Lenacapavir is a first-in-class capsid inhibitor that demonstrates picomolar HIV-1 inhibition as a monotherapy in vitro, little to no cross-resistance with...
- Indication
Lenacapavir, in combination with other antiretroviral(s), is indicated for the treatment of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults who are experiencing a failure of their current antiretroviral regimen due to resistance, intolerance, or safety considerations.
- Associated Conditions
- Multidrug resistant HIV-1 infection
- Associated Therapies
- -
Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 75
- Registration Number
- NCT06532656
- Locations
- 🇿🇦
Setshaba Research Centre, Soshanguve, South Africa
🇿🇦Stellenbosch University, Worcester, South Africa
🇿🇦Perinatal HIV Research Unit, Johannesburg, Gauteng, South Africa
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy
- Conditions
- Interventions
- First Posted Date
- 2024-03-27
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 546
- Registration Number
- NCT06333808
- Locations
- 🇦🇷
Fundacion Huesped, Buenos Aires, Argentina
🇨🇦Regina General Hospital, Regina, Canada
🇩🇪Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen
- Conditions
- Interventions
- First Posted Date
- 2022-08-16
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 689
- Registration Number
- NCT05502341
- Locations
- 🇰🇷
Chungnam National University Hospital, Daejeon, Korea, Republic of
🇰🇷Yonsei University Severance Hospital, Seoul, Korea, Republic of
🇰🇷The Catholic University of Korea Seoul St. Mary's Hospital, Seoul, Korea, Republic of
Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Lenacapavir Administered Subcutaneously in Human Immunodeficiency Virus (HIV) -1 Infected Adults
- Conditions
- Interventions
- First Posted Date
- 2018-11-14
- Last Posted Date
- 2021-04-09
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 53
- Registration Number
- NCT03739866
- Locations
- 🇺🇸
Orlando Immunology Center PA, Orlando, Florida, United States
🇺🇸Mills Clinical Research, Los Angeles, California, United States
🇺🇸The Lundquist Institute for BioMedical Innovation at Harbor-UCLA Medical Center, Torrance, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.